|
Abbrev |
Full Spell-Out |
|
2D |
two-dimensional |
|
3D |
three-dimensional |
|
3D-CRT |
three-dimensional conformal radiation therapy |
|
5-FU |
5-fluoro uracil |
|
ABMT |
autologous bone marrow transplant |
|
abnl |
abnormal |
|
ACTH |
adrenocorticotropic hormone |
|
ADH |
antidiuretic hormone |
|
adj |
adjuvant |
|
Adr |
Adriamycin |
|
AFP |
alpha-feto protein |
|
AIDS |
acquired immune deficiency syndrome |
|
AJCC |
American Joint Committee on Cancer |
|
aka |
also known as |
|
alk phos |
alkaline phosphatase |
|
am |
morning (ante meridian) |
|
ANC |
absolute neutrophil count (lab) |
|
ant |
anterior |
|
anterolat |
anterolateral |
|
AP |
anterior-posterior |
|
APC |
adenomatous polyposis coli (gene mutation) |
|
ARUBA |
A Randomized Trial of Unruptured Brain Arteriovenous Malformations |
|
ASCUS |
atypical squamous cells of unknown significance |
|
ASTRO |
American Society for Therapeutic Radiation and Oncology |
|
AUC |
area under the curve |
|
avg |
average |
|
BAT |
B-mode acquisition and targeting |
|
b/c |
because |
|
β-HCG |
beta-human chorionic gonadotropin |
|
bid |
twice daily |
|
bilat |
bilateral |
|
BM |
bone marrow |
|
BMI |
body mass index |
|
BMP |
basic metabolic panel |
|
BMT |
bone marrow transplant |
|
BTSG |
Brain Tumor Study Group |
|
Bx |
biopsy/biopsies |
|
C |
cervical (spine level) |
|
CA 19-9 |
cancer antigen 19-9 |
|
CA 125 |
cancer antigen 125 |
|
CALGB |
Cancer and Leukemia Group B |
|
C/A/P |
chest/abdomen/pelvis |
|
CBC |
complete blood count (lab) |
|
CCCG |
Colorectal Cancer Collaborative Group |
|
cCR |
clinical complete response |
|
CD |
cone-down |
|
CD4 |
cluster of differentiation 4 (for immune cells) |
|
CEA |
carcinoembryonic antigen |
|
CESS |
Cooperative Ewing Sarcoma Study |
|
CHART |
Continuous Hyperfractionated Accelerated Radiotherapy Trial |
|
chemo |
chemotherapy |
|
CHF |
congestive heart failure |
|
CIN |
cervical intraepithelial neoplasia |
|
CIS |
carcinoma in situ |
|
cm |
centimeter/centimeters |
|
CMP |
complete metabolic panel (lab) |
|
c-myc |
(gene) |
|
cN0 |
clinically node-negative |
|
CN |
cranial nerve |
|
CNS |
central nervous system |
|
Co-60 |
cobalt-60 |
|
COG |
Children's Oncology Group |
|
contralat |
contralateral |
|
Cr |
creatinine |
|
CR |
complete response |
|
CRT |
chemoradiation |
|
CSF |
cerebrospinal fluid |
|
CSI |
craniospinal irradiation |
|
CSM |
cancer-specific mortality |
|
CSS |
cause-specific survival |
|
CT |
computed tomography |
|
CTV |
clinical target volume |
|
CXR |
chest x-ray |
|
D/C |
discontinue/discontinued |
|
D&C |
dilation and curettage |
|
DCC |
deleted in colorectal cancer (gene) |
|
DDx |
differential diagnosis |
|
DFS |
diseasefree survival |
|
DLCO |
lung diffusion capacity testing |
|
DM |
distant metastasis |
|
DMFS |
distant metastasisfree survival |
|
DOI |
depth of invasion |
|
DRE |
digital rectal examination |
|
DSS |
disease-specific survival |
|
DVH |
dose volume histogram |
|
DVT |
deep venous thrombosis |
|
Dx |
diagnosis/diagnoses |
|
Dz |
disease/diseases |
|
EB |
external beam |
|
EBRT |
external beam radiation therapy |
|
EBV |
Epstein-Barr virus |
|
ECE |
extracapsular extension |
|
ECOG |
Eastern Cooperative Oncology Group |
|
EFS |
eventfree survival |
|
e.g. |
for example |
|
EGFR |
epidermal growth factor receptor |
|
ENI |
elective nodal irradiation |
|
EORTC |
European Organisation for Research and Treatment of Cancer |
|
ESR |
erythrocyte sedimentation rate (lab) |
|
et al. |
and others |
|
EUA |
exam under anesthesia |
|
EUS |
endoscopic ultrasound |
|
exam |
examination |
|
FDA |
Food and Drug Administration |
|
FDG |
fluorine-18 2-fluoro-2-deoxy-D-glucose |
|
FEV |
forced expiratory volume |
|
FFS |
failurefree survival |
|
FIGO |
International Federation of Gynecology and Obstetrics |
|
FISH |
fluorescence in situ hybridization |
|
FKHR |
Forkhead (drosophilia) homolog 1 (rhabdomyosarcoma) (gene) |
|
FLAIR |
fluid attenuation inversion recovery |
|
F:M |
female to male ratio |
|
FN rate |
false-negative rate |
|
FNA |
fine needle aspiration |
|
FOLFOX |
5-FU/leukovorin/oxaliplatin |
|
FPR |
false-positive rate |
|
FSH |
follicle-stimulating hormone |
|
FSR |
fractionated stereotactic radiotherapy |
|
fx |
fraction/fractions |
|
GERD |
gastroesophageal reflux disease |
|
GH |
growth hormone |
|
GI |
gastrointestinal |
|
GnRH |
gonadotropin-releasing hormone |
|
GTR |
gross total resection |
|
GTV |
gross target volume |
|
GU |
genitourinary |
|
Gy |
Gray |
|
gyn |
gynecologic |
|
H&N |
head and neck |
|
H&P |
history and physical |
|
HA |
headache |
|
HAART |
highly active antiretroviral therapy |
|
HCG |
human chorionic gonadotropin (lab test) |
|
HDR |
high dose rate |
|
Hgb |
hemoglobin |
|
HGSIL |
high-grade squamous intraepithelial lesion |
|
HIV |
human immunodeficiency virus |
|
HNPCC |
hereditary nonpolyposis colon cancer |
|
HPV |
human papilloma virus |
|
hr/hrs |
hour/hours |
|
HR |
hazard ratio |
|
HRT |
hormone replacement therapy |
|
HSV |
herpes simplex virus |
|
HTN |
hypertension |
|
Hx |
history/histories |
|
IBCSG |
International Breast Cancer Study Group |
|
ICP |
intracranial pressure |
|
IDL |
isodose line |
|
i.e. |
that is |
|
IELCAP |
International Early Lung Cancer Action Project |
|
IFN |
interferon |
|
IgA |
immunoglobulin A |
|
IGF |
insulinlike growth factor |
|
IgG |
immunoglobulin G |
|
IGRT |
image-guided radiation therapy |
|
IJROBP |
International Journal of Radiation Oncology, Biology, and Physics |
|
IMRT |
intensity-modulated radiation therapy |
|
inf |
inferior |
|
INR |
international normalized ratio |
|
intraop |
intraoperative |
|
IORT |
intraoperative radiation therapy |
|
ipsi |
ipsilateral |
|
IQ |
intelligence quotient |
|
ITV |
internal target volume |
|
IVC |
inferior vena cava |
|
JAMA |
Journal of the American Medical Association |
|
JCO |
Journal of Clinical Oncology |
|
JCOG |
Japan Clinical Oncology Group |
|
JCRT |
Joint Center for Radiation Therapy |
|
JNCI |
Journal of the National Cancer Institute |
|
L |
lumbar (spine level) |
|
lab |
laboratory/laboratory test |
|
LAD |
lymphadenopathy |
|
LAMP |
Locally Advanced Multimodality Protocol |
|
LAO |
left anterior oblique |
|
lat |
lateral |
|
LC |
local control |
|
LDH |
lactate dehydrogenase |
|
LDR |
low dose rate |
|
LEEP |
loop electrosurgical excision procedure |
|
LF |
local failure |
|
LFT |
liver function test |
|
LGSIL |
low-grade squamous intraepithelial lesion |
|
LH |
luteinizing hormone |
|
LINAC |
linear accelerator |
|
LLL |
left lower lobe |
|
LML |
left middle lobe |
|
LN |
lymph node |
|
LND |
lymph node dissection |
|
LOH |
loss of heterozygosity |
|
LP |
lumbar puncture |
|
LPO |
left posterior oblique |
|
LR |
local recurrence |
|
LRC |
locoregional control |
|
LRF |
locoregional failure |
|
LRFS |
local recurrencefree survival |
|
LRR |
locoregional recurrence |
|
LUL |
left upper lobe |
|
LVI |
lymphovascular invasion |
|
LVSI |
lymphovascular stromal invasion |
|
MALT |
mucosa-associated lymphoid tissue |
|
max |
maximal/maximum |
|
MDACC |
MD Anderson Cancer Center |
|
med |
medication |
|
MEN |
multiple endocrine neoplasia |
|
mets |
metastasis/metastases |
|
M:F |
male to female ratio |
|
MFS |
metastasesfree survival |
|
MGMT |
O6-methylguanine DNA-methyltransferase |
|
min |
minimal/minimum |
|
mo/mos |
month/months |
|
MRC |
Medical Research Council |
|
MRI |
magnetic resonance imaging |
|
MS |
median survival |
|
MTD |
maximum tolerated/tolerable dose |
|
MVA |
multivariate analysis |
|
N/C |
nuclear to cytoplasm ratio |
|
NCCN |
National Comprehensive Cancer Network |
|
NCCTG |
North Central Cancer Treatment Group |
|
NCI |
National Cancer Institute |
|
NCIC |
National Cancer Institute of Canada |
|
NED |
no evidence of disease |
|
NEJM |
New England Journal of Medicine |
|
neoadj |
neoadjuvant |
|
NF |
neurofibromatosis |
|
NPV |
negative predictive value |
|
NR |
no response |
|
NSABP |
National Surgical Adjuvant Breast and Bowel Project |
|
NSAID |
nonsteroidal anti-inflammatory drug |
|
NSS |
not statistically significant |
|
NTR |
near-total resection |
|
n/v |
nausea/vomiting |
|
NZ |
New Zealand |
|
OR |
odds ratio |
|
ORR |
overall response rate |
|
OS |
overall survival |
|
PA |
posterior-anterior |
|
PAP |
Papanicolau |
|
PCI |
prophylactic cranial irradiation |
|
PCP |
pneumocystic pneumonia |
|
PCR |
polymerase chain reaction |
|
pCR |
pathologic complete response |
|
PDGFR |
platelet-derived growth factor receptor |
|
PEG (tube) |
percutanous endoscopic gastrostomy tube |
|
periop |
perioperative |
|
PET |
positron emission tomography |
|
PFS |
progressionfree survival |
|
PFT |
pulmonary function test |
|
Plt |
platelets |
|
pm |
afternoon (post meridian) |
|
pN0 |
pathologically node negative |
|
PNET |
primitive neuroectodermal tumor |
|
PNI |
perineural invasion |
|
PORT |
postoperative radiation therapy |
|
post |
posterior |
|
posterolat |
posterolateral |
|
postop |
postoperative |
|
PPV |
positive predictive value |
|
PR |
partial response |
|
preop |
preoperative |
|
PSA |
prostate-specific antigen |
|
pt/pts |
patient/patients |
|
PTHrP |
parathyroid hormone–related peptide |
|
PT |
prothrombin time |
|
PTV |
planning target volume |
|
PUVA |
psoralen and long-wave ultraviolet radiation |
|
q |
every |
|
qd |
daily |
|
QOL |
quality of life |
|
RAO |
right anterior oblique |
|
RBE |
relative biologic effectiveness |
|
RCT |
randomized controlled trial |
|
rcv |
receive/received |
|
RFS |
relapsefree survival |
|
RLL |
right lower lobe |
|
RML |
right middle lobe |
|
r/o |
rule out |
|
RPO |
right posterior oblique |
|
RR |
relative risk |
|
RT |
radiation or radiation therapy |
|
RTOG |
Radiation Therapy Oncology Group |
|
RUL |
right upper lobe |
|
RUQ |
right upper quadrant |
|
Rx |
prescription/prescriptions |
|
S |
sacral (spine level) |
|
SBO |
small bowel obstruction |
|
SEER |
Surveillance Epidemiology and End Results (data) |
|
SFOP |
French Society of Pediatric Oncology |
|
SIADH |
syndrome of inappropriate secretion of antidiuretic hormone |
|
SIL |
squamous intraepithelial lesion |
|
SQ |
subcutaneous |
|
s/p |
status post |
|
SPECT |
single photon emission computed tomography |
|
SRS |
stereotactic radiosurgery |
|
SS |
statistically significant |
|
SSD |
source to skin distance |
|
STD |
sexually transmitted disease |
|
STR |
subtotal resection |
|
sup |
superior |
|
SVC |
superior vena cava |
|
Sx |
symptom/symptoms |
|
T |
thoracic (spine level) |
|
TD |
tolerance dose |
|
TFT |
thyroid function test |
|
tid |
three times a day |
|
TNM |
Tumor/Node/Metastasis |
|
trilat |
trilateral |
|
TRUS |
transrectal ultrasound |
|
TSH |
thyroid-stimulating hormone |
|
Tx |
treatment/treatments |
|
UA |
urinalysis |
|
UCSF |
University of California at San Francisco |
|
UK |
United Kingdom |
|
unilat |
unilateral |
|
US |
ultrasound |
|
U.S. |
United States |
|
UV |
ultraviolet |
|
vs. |
versus |
|
WBC |
white blood cell |
|
WBRT |
whole brain radiation therapy |
|
WHO |
World Health Organization |
|
wk/wks |
week/weeks |
|
WLE |
wide local excision |
|
yo |
year old/years old |
|
yr/yrs |
year/years |
|
Symbols |
|
|
+ |
meaning with or and (as in Surgery + RT) |
|
→ |
meaning followed by |
|
↑ |
meaning increasing, high(er), or elevated |
|
↓ |
meaning decreasing or low(er) |